Economic portfolio
Baroda BNP Paribas Health and Wellness Fund
BARODABNP Baroda BNP Paribas Mutual Fund Aug 2026 — Sep 2026 2 months
Data periodFund holdingsSep 2026NSE prices23 Oct 2026Data status →
Days to sell half: 1.0 — selling half of every holding at 20% of each stock’s usual daily NSE trading, the time to get through 90% of the portfolio (Sep 2026). Quick to unwind on normal volumes. Small-cap comparison →
Shares of this fund’s disclosed Indian listed equity, valued at official NSE closing prices. Cash, debt, derivatives and overseas holdings are not included, so for a hybrid or debt fund these are shares of its equity part only. Not performance, and not a recommendation.
Sector mix
Share of the equity shown · NSE industry
Funds most like this one
Overlap of disclosed equity · the smaller share of each company both hold, added up
- EODWHFEdelweiss · 19 shared64.3%
- Mirae Asset Nifty 500 Healthcare ETFMirae Asset · 24 shared64.2%
- Mirae Asset Healthcare FundMirae Asset · 18 shared62.2%
- DSP Nifty Healthcare ETFDSP · 16 shared61.1%
- DSP Nifty Healthcare Index FundDSP · 16 shared61.1%
- ICICI Prudential Nifty Healthcare ETFICICI Prudential · 16 shared61.1%
- Axis NIFTY Healthcare ETFAxis · 16 shared61.1%
- ADITYA BIRLA SUN LIFE NIFTY HEALTHCARE ETFAditya Birla Sun Life · 16 shared61.1%
Select one to see exactly what the two funds share. Index funds and ETFs tracking the same index overlap almost completely.
What changed in Sep 2026
This portfolio’s consecutive disclosures · evidenced adjustments applied
New positions
Complete exits
Largest increases
Largest reductions
- 01 Metropolis Healthcare Limited-7.7% -10,000
- 02 Emcure Pharmaceuticals Limited-7.8% -5,110
- 03 IPCA Laboratories Limited-3.1% -5,000
- 04 Glenmark Pharmaceuticals Limited-7.1% -5,000
- 05 AstraZeneca Pharma India Limited-15.4% -4,000
- 06 Procter & Gamble Health Limited-69.3% -3,467
- 07 Divi's Laboratories Limited-4.5% -1,925
- 08 Acutaas Chemicals Limited-2.9% -1,040
Share quantities, not market values or cash flows.
Holdings by value
Sep 2026 · largest 100 · share of the equity shown
| Company | Sector | Size | Share of equity | Value | Shares held | Held since |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Healthcare | Large Cap | 8.84% | 41.83 Cr | 0.02 Cr | by Aug 2026 (2 mo+) |
| Torrent Pharmaceuticals Limited | Healthcare | Large Cap | 8.12% | 38.40 Cr | 80,000 | by Aug 2026 (2 mo+) |
| Divi's Laboratories Limited | Healthcare | Large Cap | 8.05% | 38.10 Cr | 41,000 | by Aug 2026 (2 mo+) |
| IPCA Laboratories Limited | Healthcare | Mid Cap | 6.31% | 29.87 Cr | 0.02 Cr | by Aug 2026 (2 mo+) |
| Laurus Labs Limited | Healthcare | Mid Cap | 6.28% | 29.70 Cr | 0.01 Cr | by Aug 2026 (2 mo+) |
| Lupin Limited | Healthcare | Mid Cap | 5.96% | 28.22 Cr | 0.01 Cr | by Aug 2026 (2 mo+) |
| Apollo Hospitals Enterprise Limited | Healthcare | Large Cap | 5.44% | 25.72 Cr | 31,500 | by Aug 2026 (2 mo+) |
| Fortis Healthcare Limited | Healthcare | Mid Cap | 4.10% | 19.40 Cr | 0.03 Cr | by Aug 2026 (2 mo+) |
| Dr. Lal Path Labs Ltd. | Healthcare | Small Cap | 3.57% | 16.89 Cr | 85,000 | by Aug 2026 (2 mo+) |
| Mankind Pharma Limited | Healthcare | Mid Cap | 3.44% | 16.27 Cr | 65,000 | by Aug 2026 (2 mo+) |
| Glenmark Pharmaceuticals Limited | Healthcare | Mid Cap | 3.21% | 15.18 Cr | 65,000 | by Aug 2026 (2 mo+) |
| Aurobindo Pharma Limited | Healthcare | Mid Cap | 3.18% | 15.05 Cr | 90,000 | by Aug 2026 (2 mo+) |
| AstraZeneca Pharma India Limited | Not classified | Small Cap | 2.88% | 13.61 Cr | 22,000 | by Aug 2026 (2 mo+) |
| Abbott India Limited | Healthcare | Mid Cap | 2.58% | 12.21 Cr | 4,500 | by Aug 2026 (2 mo+) |
| Emcure Pharmaceuticals Limited | Healthcare | Small Cap | 2.46% | 11.66 Cr | 60,000 | by Aug 2026 (2 mo+) |
| Acutaas Chemicals Limited | Healthcare | Small Cap | 2.43% | 11.48 Cr | 35,000 | by Aug 2026 (2 mo+) |
| Zydus Lifesciences Limited | Healthcare | Mid Cap | 2.31% | 10.92 Cr | 94,000 | by Aug 2026 (2 mo+) |
| Max Financial Services Limited | Financial Services | Mid Cap | 2.28% | 10.78 Cr | 78,498 | by Aug 2026 (2 mo+) |
| Aster DM Quality Care Limited | Healthcare | Small Cap | 2.21% | 10.46 Cr | 0.01 Cr | by Aug 2026 (2 mo+) |
| Concord Biotech Limited | Healthcare | Small Cap | 2.18% | 10.30 Cr | 75,000 | by Aug 2026 (2 mo+) |
| Ajanta Pharma Limited | Healthcare | Small Cap | 1.61% | 7.60 Cr | 21,000 | by Aug 2026 (2 mo+) |
| Symbiotec Pharmalab Limited | Not classified | — | 1.51% | 7.15 Cr | 60,720 | by Aug 2026 (2 mo+) |
| Nephrocare Health Services Limited | Healthcare | Small Cap | 1.46% | 6.93 Cr | 0.01 Cr | by Aug 2026 (2 mo+) |
| Metropolis Healthcare Limited | Healthcare | Small Cap | 1.37% | 6.50 Cr | 0.01 Cr | by Aug 2026 (2 mo+) |
| Dr. Reddy's Laboratories Limited | Healthcare | Large Cap | 1.30% | 6.17 Cr | 50,000 | by Aug 2026 (2 mo+) |
| Manipal Health Enterprises Limited | Not classified | — | 1.27% | 6.00 Cr | 84,750 | by Aug 2026 (2 mo+) |
| Gland Pharma Limited | Healthcare | Small Cap | 1.23% | 5.80 Cr | 20,000 | by Aug 2026 (2 mo+) |
| Cipla Limited | Healthcare | Large Cap | 1.14% | 5.38 Cr | 40,000 | by Aug 2026 (2 mo+) |
| Narayana Hrudayalaya Ltd. | Healthcare | Mid Cap | 1.00% | 4.75 Cr | 26,500 | Sep 2026 (1 mo) |
| Inventurus Knowledge Solutions Limited | Information Technology | Small Cap | 0.92% | 4.37 Cr | 25,000 | by Aug 2026 (2 mo+) |
| GlaxoSmithKline Pharmaceuticals Limited | Healthcare | Mid Cap | 0.70% | 3.32 Cr | 12,000 | by Aug 2026 (2 mo+) |
| Life Insurance Corporation Of India | Financial Services | Large Cap | 0.48% | 2.28 Cr | 57,675 | by Aug 2026 (2 mo+) |
| Procter & Gamble Health Limited | Healthcare | Small Cap | 0.18% | 0.85 Cr | 1,533 | by Aug 2026 (2 mo+) |
Half of its current holdings have been held for 2 disclosed months or more without a break. “By” means held in the first month we have for this fund, so possibly for longer. Counted over this fund’s own monthly disclosures; a merger (e.g. HDFC into HDFC Bank, July 2023) starts a new run for the surviving company.
Recent position changes
Latest 100 company-month records · evidenced adjustments applied
| Company | Month | Activity | Adjusted change |
|---|---|---|---|
| Medplus Health Services Limited | Sep 2026 | ▼ Complete exit | -70,000 |
| Narayana Hrudayalaya Ltd. | Sep 2026 | ▲ New position | +26,500 |
| Metropolis Healthcare Limited | Sep 2026 | ▼ Reducing | -10,000 |
| Emcure Pharmaceuticals Limited | Sep 2026 | ▼ Reducing | -5,110 |
| Nephrocare Health Services Limited | Sep 2026 | ▲ Increasing | +5,000 |
| IPCA Laboratories Limited | Sep 2026 | ▼ Reducing | -5,000 |
| Glenmark Pharmaceuticals Limited | Sep 2026 | ▼ Reducing | -5,000 |
| AstraZeneca Pharma India Limited | Sep 2026 | ▼ Reducing | -4,000 |
| Procter & Gamble Health Limited | Sep 2026 | ▼ Reducing | -3,467 |
| Divi's Laboratories Limited | Sep 2026 | ▼ Reducing | -1,925 |
| Acutaas Chemicals Limited | Sep 2026 | ▼ Reducing | -1,040 |
| Apollo Hospitals Enterprise Limited | Sep 2026 | ▲ Increasing | +500 |
Changes compare consecutive month-end disclosures for this portfolio only.